• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Contact lens manufacturer Safigel acquired by Rome-based Bruno Pharmaceuticals

Article

Contact lens maker Safigel was acquired by Bruno Pharmaceuticals S.P.A., a privately held, family owned, Italian pharmaceutical company based in Rome.

Chicago-Contact lens maker Safigel announced that the company was recently acquired by Bruno Pharmaceuticals S.P.A., a privately held, family owned, Italian pharmaceutical company based in Rome.

According to Safigel, Bruno shares a kindred synergy with Safigel’s mission, “to provide new, groundbreaking alternatives to eye-care professionals (ECPs) who fit patients with contact lenses, and to stay on the cutting-edge of bringing major technological innovations to the eye-care marketplace that benefit contact lens wearers.”

According to Vincenzo Bruno, Italian Chief Executive Officer, the two companies will “offer even more” to U.S. ECPs in the coming months.

Although details of the transaction were not disclosed, Safigel said in a statement that it will now expand its sales and marketing efforts on its sodium hyaluronate contact lens, which has seen steady growth.

For more articles in this issue of InDispensable, click here.

Related Videos
Charles Leclercq, CEO of ARxVision, details the new ARx AI headset and its uses
© 2024 MJH Life Sciences

All rights reserved.